PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition

PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition

Summary

Mergers and Acquisitions of companies and facilities have been a high profile feature of the pharmaceutical CMO industry in current times. Acquisition deals consistently receive high profile coverage in industry news media, with questions surrounding valuations, strategic intent and which companies are potentially next targets continuously debated in the industry.

There were 130 acquisitions of service providers during the three-year period from 2015-2017. The majority of acquisitions targeted contract manufacturing organizations (CMOs) that focused on APIs-small molecule, dose, and analytical services. Nearly 70% of acquirers of services companies were strategic acquirers, that is, they were operating companies rather than investment firms. A few services companies changed hands as a consequence of the purchase of their parent company, while several CMOs were acquired by bio/pharma companies seeking to secure product supply.

More than half of acquirers were public companies, although 36% of company acquisitions were by PE firms or by CMOs owned by PE firms, with a high level of influence on the industry. Companies with complex technologies, including biologics manufacturing, are likely to be sought-after targets, as well as CMOs with specialized capabilities. However, in the coming years, M&A activity will be hindered by higher interest rates, uncertain trade and investment policies, high valuation expectations, and sizeable debt loads carried by some of the most active acquirers.

The report "PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" analyzes merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry during the period 2015-2017. The services considered in this report are contract manufacturing of active pharmaceutical ingredients (APIs) and finished dose products, associated analytical services, and packaging. Contract research providers were excluded.

Scope

• Helps bio/pharmaceutical manufacturing, development, and supply chain executives understand the implications of M&A activity on their supply base and sourcing options.


• Helps executives at CMOs and associated contract services companies and investors to recognize the significance of M&A activities for the competitive dynamics of the industry and how company strategies must change to address the altering market.


• To gain insights that might enable predictions of the nature and implications of M&A activity in the next three to five years.

Reasons to Buy

This 52-page report gives important, expert insight you won’t find in any other source. 28 tables and figures throughout the report illustrate major points and trends. This report is required reading for -

• CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking


• Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence


• Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking.